BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

KAI Pharmaceuticals, Inc. (Acquired by Amgen) 

270 Littlefield Road

South San Francisco  California  94080  U.S.A.
Phone: 650-244-1100 Fax:


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Pharmaceutical






 Company News
Amgen (AMGN) Completes Acquisition of KAI Pharmaceuticals, Inc. 7/6/2012 9:23:25 AM
Amgen (AMGN) to Pay $315 Million for Privately-Held KAI Pharmaceuticals, Inc. 4/10/2012 7:47:19 AM
KAI Pharmaceuticals, Inc. Announces Initiation of Second Phase 2 Study of KAI-4169 1/6/2012 6:39:42 AM
KAI Pharmaceuticals, Inc. Announces Late Breaker Poster Presentation of KAI-4169 Phase 2 Clinical Results at the American Society of Nephrology’s Kidney Week 2011 11/11/2011 6:46:27 AM
KAI Pharmaceuticals, Inc. Inks $13 Million Development Deal with Ono Pharmaceutical Company, Ltd. 9/15/2011 6:44:31 AM
KAI Pharmaceuticals, Inc. Announces Promising Results of KAI-4169 Program for the Treatment of Chronic Kidney Disease-Mineral and Bone Disorder 6/7/2011 8:40:42 AM
KAI Pharmaceuticals, Inc. Announces Advancement of KAI-4169 Clinical Program into a Phase 2 Trial 3/14/2011 10:03:31 AM
KAI Pharmaceuticals, Inc. Announces Initiation of Phase 1b Study of KAI-4169 for the Treatment of Secondary Hyperparathyroidism (SHPT) 9/27/2010 10:06:05 AM
KAI Pharmaceuticals, Inc. Announces Phase 1 Results of KAI-4169 for the Treatment of Secondary Hyperparathyroidism (SHPT) 7/20/2010 8:27:22 AM
Altea Therapeutics and KAI Pharmaceuticals, Inc. Enter into a Preclinical and Clinical Development Agreement for the Transdermal Delivery of Certain Novel KAI Peptides 1/13/2010 9:32:04 AM
1234